The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | MEDALIST: OS & risk of disease progression in patients with MDS treated with luspatercept
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses overall survival results from the Phase III MEDALIST trial (NCT02631070), which investigated the use of luspatercept for patients with low-risk myelodysplastic syndromes (MDS). Overall survival was found to be comparable in the experimental and placebo arms of the trial. Dr Platzbecker also discusses the results of an analysis of the risk of patients progressing to high-risk MDS or acute myeloid leukemia (AML). Data from the trial showed that there was a comparable risk of disease progression in the experimental and placebo arms. The trial also reported that patients who responded to luspatercept had better survival outcomes than those who didn’t respond. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Geron: Honoraria; Jazz: Honoraria; Abbvie: Honoraria; BMS/Celgene: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Silence Therapeutics: Honoraria; Janssen: Honoraria.
